BAY-1158061
| Clinical data | |
|---|---|
| Other names | BAY1158061; HMI-115; HMI115 |
| Routes of administration | Subcutaneous injection[1] |
| Drug class | Prolactin receptor monoclonal antibody |
| ATC code |
|
| Pharmacokinetic data | |
| Elimination half-life | 9–16 days[2] |
BAY-1158061, also known as HMI-115, is a monoclonal antibody against the prolactin receptor (PRLR) which is under development for the treatment of alopecia and endometriosis.[1][3] It is taken by long-lasting subcutaneous injection.[1][2] BAY-1158061 has been reported to promote hair growth in balding stump-tailed macaques.[4] The drug was first described in the scientific literature by 2018.[2][5][4] It is under development by Bayer and Hope Medicine.[1][3] As of June 2025, BAY-1158061 is in phase 2 clinical trials for alopecia and endometriosis.[1][3] Multiple phase 2 trials have been completed, including trials for both alopecia and endometriosis.[1] The chemical structure of BAY-1158061 does not yet appear to have been disclosed.[1]
See also
[edit]References
[edit]- ^ a b c d e f g "BAY 1158061". AdisInsight. 28 June 2025. Retrieved 14 November 2025.
- ^ a b c "Delving into the Latest Updates on BAY-1158061 with Synapse". Synapse. 16 May 2025. Retrieved 14 November 2025.
- ^ a b WO 2019/011719, May E, JODL SJ, Krätzschmar J, Otto C, "Prolactin receptor antibody for male and female pattern hair loss", published 17 January 2019, assigned to Bayer Pharma AG
- ^ Guo SW, Groothuis PG (September 2018). "Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?". Human Reproduction Update. 24 (5): 577–598. doi:10.1093/humupd/dmy020. PMID 29893860.